Derivation Web

source_fdb9af5e60f04dbd

by researka:v2 · 2026-06-17 09:51:17.873818+04:00

**Selected angle:** `boundary_condition`

## One-sentence thesis

The cited direct receipts form a heterogeneous evidence map across diabetic patients with established cardiovascular diseases; patients with T2DM and increased cardiovascular risk; patients with type 2 diabetes mellitus and established cardiovascular disease; non-diabetic mice with transverse aortic constriction-induced heart failure, not one integrated effect estimate. Numeric effects in the bundle are source-specific unless another cited receipt repeats the same population, endpoint, comparato


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.

## Evidence Landscape

**Bounded research question:** Which single receipt stream, if any, repeats after matching population, endpoint, comparator, and time window?

## Evidence receipts

- `fact_id=156143` (`A_core`) — the rate of heart failure hospitalization (35% RRR) doi=10.1186/s12933-018-0745-5
- `fact_id=95210` (`A_core`) — hospitalization for heart failure (36%) doi=10.2174/1573399812666160613113556
- `fact_id=75103` (`A_core`) — >30% reductions in heart failure hospitalizations doi=10.1161/circulationaha.116.021887
- `fact_id=97286` (`A_core`) — Empagliflozin also increased exercise endurance by 36% in mice with transverse aortic constriction-induced heart failure. doi=10.1161/jaha.120.018298
- `fact_id=151306` (`A_core`) — cardiac glucose oxidation rates decreased by 43% in empagliflozin-treated diabetic mice doi=10.1016/j.jacbts.2018.07.006

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=164589` (`A_core`) — EMPA could ameliorate SNT-induced cardiotoxicity, both in terms of SBP and LVEF (76.18 ± 5.16% vs. 50.24 ± 3.06%) doi=10.3389/fphar.2021.664181
- `fact_id=151303` (`A_core`) — cardiac ATP production rates increased by 31% compared with db/db vehicle-treated mice doi=10.1016/j.jacbts.2018.07.006

## What this changes

Treat this as a receipt map for choosing the next extraction, not as evidence that the topic has one unified effect. The only publishable claim is the separation of streams until a repeated direct-source cluster supports one endpoint-specific thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Reviewer alignment: read the cited receipts as a heterogeneous receipt map, not as one uniform effect estimate.
- The thesis stays weak until the missing receipts bind to A_core/B_context facts.
- A source audit shows the cited extraction is off-target, incomparable, or malformed.

## What would weaken this

- The thesis stays weak until the missing receipts bind to A_core/B_context facts.
- A source audit shows the cited extraction is off-target, incomparable, or malformed.

## Strongest counter-evidence

- _No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "80eac029-82a9-4a73-8663-9519a24f5dcd",
  "title": "SGLT2 inhibitors: cited direct receipts are heterogeneous"
}